Abstract
Elucidating the impact of cancer treatments on ovarian reserve is central to fertility preservation decisions, but longitudinal measures of ovarian reserve markers like anti-mullerian hormone (AMH) in traditional prospective cohort studies are challenged by cost, sample size, and follow up. We hypothesized that AMH trajectories derived from administrative health claims data would differ by breast cancer status and chemotherapy exposures.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
